Zhao Wei, Dong Shuang, Duan Bensong, Chen Ping, Shi Lei, Gao Hengjun, Qi Haizhi
Organ Transplantation Center, Second Xiangya Hospital, Central South University Changsha, Hunan 410011, China.
Department of Gastroenterology, Tongji Hospital, Tongji University School of Medicine Shanghai 200065, China.
Am J Transl Res. 2015 Jul 15;7(7):1295-302. eCollection 2015.
Accumulating evidence suggests that long non-coding RNA (lncRNA) HOTAIR participates in many types of cancer such as gastric cancer and may confer malignant phenotype to tumor cells. Fluorouracil and platinum combination chemotherapy is the first line therapy for gastric cancer. However, it is still unknown whether HOTAIR influences the outcome of cancer patients treated with chemotherapy. This study aimed to evaluate the association of HOTAIR expression with the prognosis of patients with advanced gastric adenocarcinoma (GA) receiving fluorouracil and platinum based chemotherapy. We examined the levels of HOTAIR in 168 GA samples using quantitative real-time PCR and analyzed its relationship with clinical features and prognosis of patients with advanced GA treated with fluorouracil and platinum based chemotherapy. Compared with paracancerous tissues, HOTAIR was significantly upregulated in GA tissues, especially in more advanced cases. High HOTAIR expression was an independent poor prognostic factor for patients with advanced GA. Further stratification analyses revealed that the association between HOTAIR expression and survival in patients with advanced GA remained significant in the subgroup of patients with TNM stages IIIA and IIIB, poorly differentiated, and smaller tumors. In conclusion, our results provide first evidence that HOTAIR may be served as a biomarker that predicts which patient with advanced GA will benefit from fluorouracil and platinum combination chemotherapy.
越来越多的证据表明，长链非编码RNA（lncRNA）HOTAIR参与了多种癌症，如胃癌，并可能赋予肿瘤细胞恶性表型。氟尿嘧啶和铂类联合化疗是胃癌的一线治疗方法。然而，HOTAIR是否会影响接受化疗的癌症患者的预后仍不清楚。本研究旨在评估HOTAIR表达与接受氟尿嘧啶和铂类化疗的晚期胃腺癌（GA）患者预后之间的关联。我们使用定量实时PCR检测了168例GA样本中的HOTAIR水平，并分析了其与接受氟尿嘧啶和铂类化疗的晚期GA患者临床特征及预后的关系。与癌旁组织相比，HOTAIR在GA组织中显著上调，尤其是在更晚期的病例中。HOTAIR高表达是晚期GA患者独立的不良预后因素。进一步的分层分析显示，在TNM分期为IIIA和IIIB、低分化和肿瘤较小的患者亚组中，HOTAIR表达与晚期GA患者生存之间的关联仍然显著。总之，我们的结果首次证明HOTAIR可能作为一种生物标志物，预测哪些晚期GA患者将从氟尿嘧啶和铂类联合化疗中获益。
